PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism Studies
Abstract
During the development of any PEGylated protein or peptide, toxicology in relevant species will be conducted prior to human exposure. Normally, comprehensive metabolism data accompany the toxicity studies for a small molecule. We have examined whether such studies would be relevant in the safety assessment of PEGylated material. Literature data indicate that the polyethylene glycol (PEG) associated with a biological molecule should provide no extra concern because the exposure-toxicity relationship of PEG in animals and humans has been thoroughly investigated and metabolism/excretion of PEG is well understood. Based on the comparisons of PEG exposure from PEGylated biological products and the exposure of PEG associated with toxicity in humans, the therapeutic index is large (approximately 600-fold or greater). Therefore, assuming that toxicological evaluation of a biological molecule of interest is complete and satisfactory therapeutic windows are achieved, the data contained in this review indicate that the PEG associated with a protein or other biological molecule does not represent an additional unquantified risk to humans.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Even for quite large polymers (up to ~200 kDa in some cases), urinary excretion can still play a major role.
“Nonetheless, even for quite large polymers (up to ~200 kDa in some cases), urinary excretion can still play a major role [254].”
From Biomaterials in Postoperative Adhesion Barriers and Uterine Tissue Engineering (2025) · cites this paper as [254]
Cited by
Sorted by citations
Turecek, P. L., Bossard, M. J., Schoetens, F., & Ivens, I. A. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.015 · Cited by 733 · see citing works
Designing degradable hydrogels for orthogonal control of cell microenvironments
Kharkar, P. M., Kiick, K. L., & Kloxin, A. M. (2013) · Chem. Soc. Rev. · doi:10.1039/c3cs60040h · Cited by 717 · see citing works
Current strategies for the design of PROTAC linkers: a critical review
Troup, R. I., Fallan, C., & Baud, M. G. J. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00018 · Cited by 424 · see citing works
PEGylated nanomedicines: recent progress and remaining concerns
Vllasaliu, D., Fowler, R., & Stolnik, S. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.866651 · Cited by 137 · see citing works
Pre-existing antibody: biotherapeutic modality-based review
Gorovits, B., Clements-Egan, A., Birchler, M., Liang, M., Myler, H., Peng, K., Purushothama, S., Rajadhyaksha, M., Salazar-Fontana, L., Sung, C., et al. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9878-1 · Cited by 85 · see citing works
Development of Quinic Acid-Conjugated Nanoparticles as a Drug Carrier to Solid Tumors
Amoozgar, Z., Park, J., Lin, Q., Weidle, J. H., & Yeo, Y. (2013) · Biomacromolecules · doi:10.1021/bm400512g · Cited by 27 · see citing works
Biomaterials in Postoperative Adhesion Barriers and Uterine Tissue Engineering
Fazel Anvari-Yazdi, A., Badea, I., & Chen, X. (2025) · Gels · doi:10.3390/gels11060441 · Cited by 20 · see citing works
Bai, J., Tang, X., Zhang, Y., Lin, J., & Li, M. (2018) · RSC Advances · doi:10.1039/c7ra12843f · Cited by 7 · see citing works
- Authors
- Webster, R., Didier, E., Harris, P., Siegel, N., Stadler, J., Tilbury, L., & Smith, D.
- Affiliations
- Pfizer (United Kingdom) (GB)
- ORCID
- Smith, Dennis
- Venue
- Drug Metabolism and Disposition
- Publisher
- Elsevier BV
- Published
- 2007-01
- Volume
- 35
- Issue
- 1
- Pages
- 9-16
- ISSN
- 0090-9556 (ISSN-L)
- OpenAlex
- W2166171010
- Cited by
- 337
- References
- 0
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 10 · 2023: 13 · 2022: 15 · 2021: 15 · 2020: 20 · 2019: 20 · 2018: 23 · 2017: 20 · 2016: 24 · 2015: 25 · 2014: 24 · 2013: 31 · 2012: 20
- FWCI
- 0.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Metabolism and Disposition (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- PEGylated proteins, polyethylene glycol, safety assessment, exposure-toxicity relationship, therapeutic window
- MeSH terms
- Animals, Humans, Polyethylene Glycols, Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
